EGFR and PI3K Signalling Pathways as Promising Targets on Circulating Tumour Cells from Patients with Metastatic Gastric Adenocarcinoma.

Humans Stomach Neoplasms / pathology ErbB Receptors / metabolism Signal Transduction / drug effects Adenocarcinoma / drug therapy Cell Line, Tumor Class I Phosphatidylinositol 3-Kinases / metabolism Neoplastic Cells, Circulating / metabolism Phosphatidylinositol 3-Kinases / metabolism Neoplasm Metastasis Phosphoinositide-3 Kinase Inhibitors / pharmacology Protein Kinase Inhibitors / pharmacology Antineoplastic Agents / pharmacology Thiazoles
3D cell culture EGFR PI3K/Akt PIK-75 alpelisib c-Met cell signalling circulating tumour cells gastric cancer gefitinib organotypics

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
20 May 2024
Historique:
received: 17 04 2024
revised: 12 05 2024
accepted: 16 05 2024
medline: 25 5 2024
pubmed: 25 5 2024
entrez: 25 5 2024
Statut: epublish

Résumé

The prognosis for metastatic gastric adenocarcinoma (mGAC) remains poor. Gene alterations in receptor tyrosine kinases (RTKs) such as epidermal growth factor receptor

Identifiants

DOI: 10.3390/ijms25105565 PMID: 38791602
pubmed: 38791602
pii: ijms25105565
doi: 10.3390/ijms25105565
pii:
doi:

Substances chimiques

ErbB Receptors EC 2.7.10.1
EGFR protein, human EC 2.7.10.1
Class I Phosphatidylinositol 3-Kinases EC 2.7.1.137
PIK3CA protein, human EC 2.7.1.137
Phosphatidylinositol 3-Kinases EC 2.7.1.-
Alpelisib 08W5N2C97Q
Phosphoinositide-3 Kinase Inhibitors 0
Protein Kinase Inhibitors 0
Antineoplastic Agents 0
Thiazoles 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Tour de Cure
ID : RSP-316-FY2023

Auteurs

Ann-Katrin Piper (AK)

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia.
Molecular Horizons, University of Wollongong, Wollongong, NSW 2522, Australia.
ORCID: 0000-0001-5805-0084

Chelsea Penney (C)

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia.
Molecular Horizons, University of Wollongong, Wollongong, NSW 2522, Australia.

Jacqueline Holliday (J)

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia.
Molecular Horizons, University of Wollongong, Wollongong, NSW 2522, Australia.

Gary Tincknell (G)

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia.
Molecular Horizons, University of Wollongong, Wollongong, NSW 2522, Australia.
Illawarra Cancer Care Centre, Wollongong Hospital, Wollongong, NSW 2500, Australia.
ORCID: 0000-0003-2611-0075

Yafeng Ma (Y)

Centre for Circulating Tumour Cell Diagnostics & Research at the Ingham Institute for Applied Medical Research, South-Western Clinical School, University of New South Wales, Liverpool, NSW 2170, Australia.
ORCID: 0000-0002-0522-8771

Sarbar Napaki (S)

Graduate School of Medicine, University of Wollongong, Wollongong, NSW 2522, Australia.
Department of Pathology, Wollongong Hospital, Wollongong, NSW 2500, Australia.

Klaus Pantel (K)

Institute for Tumor Biology, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
ORCID: 0000-0001-5736-2772

Daniel Brungs (D)

Molecular Horizons, University of Wollongong, Wollongong, NSW 2522, Australia.
Illawarra Cancer Care Centre, Wollongong Hospital, Wollongong, NSW 2500, Australia.
Graduate School of Medicine, University of Wollongong, Wollongong, NSW 2522, Australia.
Department of Pathology, Wollongong Hospital, Wollongong, NSW 2500, Australia.

Marie Ranson (M)

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia.
Molecular Horizons, University of Wollongong, Wollongong, NSW 2522, Australia.
ORCID: 0000-0002-5570-9645

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › EGFR and PI3K Signalling Pathways as Promising...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Maladies de l'estomac › Tumeurs de l'estomac › EGFR and PI3K Signalling Pathways as Promising...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs peptidiques › Récepteur facteur croissance › Récepteurs ErbB › EGFR and PI3K Signalling Pathways as Promising...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › EGFR and PI3K Signalling Pathways as Promising...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs épithéliales épidermoïdes et glandulaires › Carcinomes › Adénocarcinome › EGFR and PI3K Signalling Pathways as Promising...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › EGFR and PI3K Signalling Pathways as Promising...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Phosphatidylinositol 3-kinases › Phosphatidylinositol-4-phosphate 3-kinase › Phosphatidylinositol 3-kinases de classe I › EGFR and PI3K Signalling Pathways as Promising...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Métastase tumorale › Cellules tumorales circulantes › EGFR and PI3K Signalling Pathways as Promising...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Phosphatidylinositol 3-kinases › EGFR and PI3K Signalling Pathways as Promising...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Métastase tumorale › EGFR and PI3K Signalling Pathways as Promising...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs des phosphoinositide-3 kinases › EGFR and PI3K Signalling Pathways as Promising...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéines kinases › EGFR and PI3K Signalling Pathways as Promising...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › EGFR and PI3K Signalling Pathways as Promising...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Azoles › Thiazoles › EGFR and PI3K Signalling Pathways as Promising...